MIRA Mira Pharmaceuticals Inc

$MIRA highlighted positive preclinical data for MIRA-55, showing significant pain reduction and inflammation relief in animal models.

$MIRA down and beat but sure to rise some day testing for these candidates come around a couple times a year

$MIRA The SKNY-1 obesity results caught my attention. Not just the reported weight loss but the potential to preserve lean mass & limit weight regain. Still mouse data though. Big difference. Premarket showed 3,220 shares at .56 followed by 950 at .55. That .60 print was one share. Interesting science. Not much conviction in the tape yet. I want to see buyers reclaim a level & actually hold it before giving this move more credit.

$MIRA 5$ soon MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide

$MIRA On October 28, 2026, MIRA Pharmaceuticals shared promising results from its study of SKNY-1, an oral drug for obesity, showing significant weight and fat loss in mice without affecting food intake. The treatment also led to less weight regain compared to semaglutide, highlighting its potential advantages.

$MIRA On October 22, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive results from a 21-day IND-enabling preclinical proof-of-concept study evaluating MIRA-55 in a validated model of chronic inflammatory pain.

huge candidate and victory is this can be bought by larger company $MIRA neuropathic pain and ptsd / anxiety orders as well can be helped with ketmir-2 and Mira-55 analogue derivatives from ketamine and marijuana non toxic compare to peers